196
Participants
Start Date
November 15, 2021
Primary Completion Date
September 21, 2025
Study Completion Date
December 21, 2025
IPG7236
The IPG7236 drug product is supplied as oral tablet dosage form, containing two strengths: 25 mg and 100 mg, respectively, which contain IPG7236.
RECRUITING
NEXT Oncology, Austin
RECRUITING
Providence Portland Medical Center, Portland
RECRUITING
The First Affiliated Hospital Nanchang Univeristy, Nanchang
RECRUITING
Shandong Cancer Hospital, Jinan
RECRUITING
Shanghai East Hospital, Shanghai
ACTIVE_NOT_RECRUITING
Shanghai General Hospital, Shanghai
RECRUITING
Shanghai GoBroad Cancer Hospital China Pharmaceutical University, Shanghai
Nanjing Immunophage Biotech Co., Ltd
INDUSTRY